Last reviewed · How we verify
U87 CAR-T
U87 CAR-T is a Small molecule drug developed by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd. It is currently in Phase 1 development.
U87 CAR-T is a type of CAR-T cell therapy being studied in clinical trials for the treatment of various types of cancer, including pancreatic cancer, solid tumors, nasopharynx cancer, and head and neck cancer. The therapy involves using a patient's own T-cells, modified with the U87 CAR, to target and attack cancer cells.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | U87 CAR-T |
|---|---|
| Sponsor | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- U87 CAR-T in Patients With Advanced Head and Neck Tumors (PHASE1)
- U87 CART in Treatment of Advanced Solid Tumor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- U87 CAR-T CI brief — competitive landscape report
- U87 CAR-T updates RSS · CI watch RSS
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd portfolio CI
Frequently asked questions about U87 CAR-T
What is U87 CAR-T?
Who makes U87 CAR-T?
What development phase is U87 CAR-T in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing